Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.